Allucent has received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to expedite clinical research and development of next-generation booster vaccines for Covid-19.
Daiichi Sankyo has announced its decision to shut down its Japanese research and development (R&D) subsidiary to further strengthen its capabilities.
Precision-medicine company Solu Therapeutics has raised $31m in seed financing to develop the Cytotoxicity Targeting Chimera (CyTaC) platform and drug candidates.
Viatris and Kindeva Drug Delivery have launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol to treat certain asthma and chronic obstructive pulmonary disease (COPD) patients.
The China National Medical Products Administration (NMPA) has accepted and granted priority review to Overland ADCT BioPharma’s biologics license application (BLA) for ZYNLONTA (loncastuximab tesirine-lpyl).
Generic and biosimilar medicines provider Sandoz has introduced a global action plan to provide patients with quick access to biologic medicines.
A global health care company Fresenius Kabi has announced the availability of Vasopressin injection, USP, in the US for treating adults with vasodilatory shock.
Charles River Laboratories International has teamed up with Korean biotechnology company Curigin for producing oncolytic ribonucleic acid interference (RNAi) gene therapy.
Private equity and growth capital firm EdgeCap Partners has acquired a majority stake in Bulgarian clinical research solutions organisation (CRO) Comac Medical.
Biopharmaceutical company Athenex and some of its subsidiaries voluntarily have filed Chapter 11 proceedings of the US Bankruptcy Code.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.